European Commission Approves Pharming's Joenja (leniolisib) for APDS Treatment

On May 22, 2026, Pharming Group N.V. announced that the European Commission (EC) granted marketing authorization for Joenja (leniolisib), an oral selective PI3K delta inhibitor. This represents the first and only approved treatment in the European Union for activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients aged 12 years and older. The approval covers all 27 EU Member States, plus Norway, Iceland, and Liechtenstein. The EC's decision was supported by results from a Phase II/III clinical trial in 31 patients, which demonstrated statistically significant improvements in immune dysregulation and immunodeficiency markers, alongside long-term safety data from an open-label extension study. Pharming expects the first European launch to occur in Germany in Q3 2026, with subsequent launches pending national reimbursement negotiations. Joenja is already approved and marketed in several other territories, including the United States and the United Kingdom. This authorization significantly expands Pharming's global commercial footprint for its rare disease portfolio.